1. Home
  2. SLN vs CDMO Comparison

SLN vs CDMO Comparison

Compare SLN & CDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • CDMO
  • Stock Information
  • Founded
  • SLN 1994
  • CDMO 1981
  • Country
  • SLN United Kingdom
  • CDMO United States
  • Employees
  • SLN N/A
  • CDMO N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • CDMO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLN Health Care
  • CDMO Health Care
  • Exchange
  • SLN Nasdaq
  • CDMO Nasdaq
  • Market Cap
  • SLN 842.4M
  • CDMO 784.1M
  • IPO Year
  • SLN N/A
  • CDMO N/A
  • Fundamental
  • Price
  • SLN $12.70
  • CDMO $12.15
  • Analyst Decision
  • SLN Strong Buy
  • CDMO Buy
  • Analyst Count
  • SLN 4
  • CDMO 5
  • Target Price
  • SLN $61.50
  • CDMO $13.63
  • AVG Volume (30 Days)
  • SLN 184.3K
  • CDMO 3.6M
  • Earning Date
  • SLN 11-14-2024
  • CDMO 12-05-2024
  • Dividend Yield
  • SLN N/A
  • CDMO N/A
  • EPS Growth
  • SLN N/A
  • CDMO N/A
  • EPS
  • SLN N/A
  • CDMO N/A
  • Revenue
  • SLN $21,773,221.00
  • CDMO $142,358,000.00
  • Revenue This Year
  • SLN N/A
  • CDMO $19.31
  • Revenue Next Year
  • SLN $104.98
  • CDMO $21.14
  • P/E Ratio
  • SLN N/A
  • CDMO N/A
  • Revenue Growth
  • SLN N/A
  • CDMO N/A
  • 52 Week Low
  • SLN $8.94
  • CDMO $4.07
  • 52 Week High
  • SLN $27.72
  • CDMO $12.48
  • Technical
  • Relative Strength Index (RSI)
  • SLN 15.31
  • CDMO 67.73
  • Support Level
  • SLN $17.11
  • CDMO $11.67
  • Resistance Level
  • SLN $18.24
  • CDMO $12.30
  • Average True Range (ATR)
  • SLN 0.89
  • CDMO 0.27
  • MACD
  • SLN -0.49
  • CDMO 0.17
  • Stochastic Oscillator
  • SLN 1.06
  • CDMO 89.03

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About CDMO Avid Bioservices Inc.

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Share on Social Networks: